ARTICLE | Emerging Company Profile
Technology showcase: BioCentury’s 2020 class of emerging companies
A snapshot of the next iteration of gene and cell therapies, gene editors, protein degraders and more
January 23, 2021 1:52 AM UTC
As emerging therapeutic modalities move toward mainstream, a flood of new companies has arisen to break through the limitations of first-generation technologies and expand the reach of gene and cell therapies, gene editing technologies, protein degraders and more across a wider swath of diseases.
BioCentury profiled 119 start-ups in 2020, providing a snapshot of where innovators and investors are driving biotech’s leading edge...